Fulcrum Therapeutics (FULC) Total Current Liabilities (2018 - 2026)

Fulcrum Therapeutics (FULC) has reported Total Current Liabilities for 9 consecutive years, with $10.3 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Total Current Liabilities rose 14.61% year-over-year to $10.3 million; the TTM figure through Jun 2026 stood at $10.3 million (up 14.61% YoY), while the FY2025 annual figure was $13.0 million, up 18.15% from the prior year.
• Total Current Liabilities grew to $10.3 million in Q2 2026 per FULC's latest filing, from $9.9 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $22.1 million in Q2 2022 and bottomed at $8.1 million in Q1 2025.
• Historically, Total Current Liabilities has averaged $13.3 million across 5 years, with a median of $13.4 million in 2023.
• Annual changes were most pronounced in 2023 — Total Current Liabilities tumbled 33.08% — and 2026, when it rose 21.78%.
• Fulcrum Therapeutics' Total Current Liabilities stood at $16.7 million in 2022, then decreased by 18.24% to $13.7 million in 2023, then dropped by 19.24% to $11.0 million in 2024, then rose by 18.15% to $13.0 million in 2025, then retreated by 21.08% to $10.3 million in 2026.
• Business Quant data shows FULC's Total Current Liabilities at $10.3 million in Q2 2026, $9.9 million in Q1 2026, and $13.0 million in Q4 2025.